Biosimilars: The Debate Continues

被引:21
作者
Colbert, Robert A. [1 ]
Cronstein, Bruce N. [2 ]
机构
[1] NIAMSD, Pediat Translat Res Branch, NIH, CRC, Bethesda, MD 20892 USA
[2] NYU, Sch Med, New York, NY USA
来源
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词
D O I
10.1002/art.30505
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
引用
收藏
页码:2848 / 2850
页数:3
相关论文
共 6 条
[1]
[Anonymous], 2011, NAT BIOTECH, V29, P1
[2]
Biosimilars encircle Rituxan, US debates innovator exclusivity [J].
Carey, Karen .
NATURE BIOTECHNOLOGY, 2011, 29 (03) :177-178
[3]
Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997-2000 [J].
Haas, JS ;
Phillips, KA ;
Gerstenberger, EP ;
Seger, AC .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (11) :891-897
[4]
Biosimilar epoetins and other "follow-on'' biologics: Update on the European experiences [J].
Jelkmann, Wolfgang .
AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (10) :771-780
[5]
Hearing shines spotlight on biosimilar controversies [J].
Mullard, Asher .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (12) :905-906
[6]
*US FDA, 2010, FED REG 1005, V75